“The spin-off will establish two separate companies, a fully integrated, pure play, eye health company built on the iconic Bausch Health brand and a long history of innovation, and an international diversified pharmaceutical company with leading physicians in gastroenterology, dermatology, aesthetics, neurology and an international pharma business,” says CEO Joseph Papa.

The company formerly known as Valeant, put together by a series of mergers, is ready to spin out the legacy Bausch + Lomb eyecare business that it used in its rebranding. 

The $2.1bn investment under the US’ Operation Warp Speed will fund development, scale-up of US manufacturing and the first 100 million doses. 

The $2.1bn investment under the US’ Operation Warp Speed will fund development, scale-up of US manufacturing and the first 100 million doses. 

As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta. 

Ibrance (palbociclib) is unlikely to succeed in the adjuvant trial, the data safety monitoring board concluded. Pfizer has another adjuvant trial due later this year.